Bepirovirsen NHS access is undecided, because the drug has no UK marketing authorisation. GSK said the US FDA approved bepirovirsen, branded Hibsago, for chronic hepatitis B on 20 October 2026. NHS patients cannot expect routine access until the MHRA authorises it and NICE completes its appraisal.
So will the NHS offer bepirovirsen? Not yet. What follows sets out what the US approval covers and what would settle the UK position.
Will the NHS Offer Bepirovirsen for Hepatitis B?
A search on 21 October 2026 found no UK marketing authorisation for bepirovirsen. The emc medicines database returned no results for the name. The GSK releases reviewed that day name US, Japanese, European and Chinese regulatory steps. They do not name an MHRA filing.
NICE has still opened an appraisal. It lists bepirovirsen as topic ID6608, a standard single technology appraisal. Scoping began on 6 March 2026, and the page gives no publication date.
The NICE final scope, dated June 2026, says bepirovirsen had no UK marketing authorisation at that point. It adds: “Guidance will only be issued in accordance with the marketing authorisation.”
That sequence matters. NICE cannot recommend a use the regulator has not authorised. Bepirovirsen NHS funding therefore depends on the MHRA acting first.
What the FDA Approved on 20 October 2026
GSK announced the approval in a release issued from Philadelphia on 20 October 2026. In an earlier release, GSK gave the FDA goal date as 26 October 2026. The decision therefore came six days early. The FDA also announced the approval on 20 October 2026. Label details here follow GSK’s approval announcement.
Who the US label covers
The US indication is chronic hepatitis B in adults without cirrhosis. Patients must have taken nucleos(t)ide analogue therapy for at least six months. They must also have suppressed HBV DNA and HBsAg at or below 3,000 IU/mL, measured by an FDA-authorised test.
Hibsago is given alongside that background therapy as a six-month course. Each dose is two injections, and patients can self-administer after the first dose. The FDA also authorised Roche’s Elecsys HBsAg II quant II RxDx assay to select and monitor patients.
What B-Well 1 and B-Well 2 showed
Two phase 3 trials, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), supported the approval. GSK describes them as randomised, double-blind and placebo-controlled, across 29 countries. EU trial records for B-Well 1 list UK sites.
The primary endpoint was functional cure. GSK defines it as undetectable HBsAg and HBV DNA for at least 24 weeks after all treatment stops. In pooled data, 233 of 1,220 patients on bepirovirsen reached it, or 19 per cent. None of the 614 patients on placebo did.
With baseline HBsAg at or below 1,000 IU/mL, 200 of 768 patients reached functional cure, or 26 per cent. None of 393 on placebo did. This was a key secondary endpoint. GSK puts the typical standard-of-care rate at about 1 per cent or lower after a year of treatment.
These are minority outcomes. About four in five treated patients in the overall population did not reach functional cure. The release gives no durability data beyond the 24-week definition. Any long-term case for bepirovirsen NHS use would need such data.
What the Boxed Warning Says
GSK describes the safety profile as acceptable. The most frequent trial events were injection site redness, local pain and a temporary rise in a liver enzyme. The US label adds a boxed warning for on-treatment hepatic flares and thrombocytopenia.
Hibsago is contraindicated with platelet counts below 100 × 10⁹ per litre before starting treatment. It is also contraindicated in cirrhosis and acute hepatic impairment. Other warnings cover worsening renal function and inflammatory reactions. They also cover omental infarction after improper injection. Hepatitis B can worsen after analogue therapy stops.
Common adverse reactions of 10 per cent or more were injection site reactions, fever, fatigue and headache. Pregnancy and renal impairment data are limited, and use under 18 is not established.
Jefferies analysts, quoted by Fierce Pharma, said monitoring demands could “work against the commercial uptake”. That is a commercial view, not a clinical one. It still points to a delivery question for NHS hepatology services.
Where Bepirovirsen NHS Access Stands Today
Japan approved Hibsago first, on 24 August 2026, according to GSK’s Japan announcement. GSK says the approval was accelerated under Japan’s SENKU designation. In Europe, GSK said on 27 March 2026 that the EMA had accepted the marketing authorisation application for review. A search on 21 October 2026 found no EU decision.
The MHRA’s International Recognition Procedure can rely on FDA or EMA approvals. Its guidance sets a 60-day Recognition A timetable and a 110-day Recognition B timetable. Recognition B is required for first-in-class new active substances, among other criteria.
GSK has called bepirovirsen a potential first-in-class medicine. Which route would apply is a regulatory judgement that is not public. No UK application has been announced, so bepirovirsen NHS timing cannot be estimated.
How Many NHS Patients Could Be Affected?
UKHSA’s 2025 hepatitis B report estimates 268,767 people live with chronic hepatitis B in England. That is a prevalence of 0.58 per cent. The 95 per cent confidence interval runs from 227,896 to 314,004.
UKHSA puts the diagnosed share at 43.6 per cent, or 117,079 people. The report covers data to the end of 2024 and was published on 19 November 2025. It covers England only.
Those figures do not show who would qualify. The US label needs prior analogue therapy, no cirrhosis and HBsAg at or below 3,000 IU/mL. A search on 21 October 2026 found no published estimate of that eligible NHS group.
The NICE scope lists the likely comparators. They are tenofovir disoproxil, entecavir, peginterferon alfa-2a, tenofovir alafenamide and no treatment. Cost-effectiveness will be judged against established antivirals. The scope also notes that the trials compared bepirovirsen with placebo in people on stable treatment.
Price is unknown. Fierce Pharma reported that GSK expects US availability before the end of 2026. It said GSK will disclose a list price after payer talks. BioSpace reported that GSK forecasts peak sales above £2 billion.
What Would Settle the Question, and When?
Four events would settle bepirovirsen NHS access. The first is an MHRA decision, by either route. The second is a European decision after the EMA review. The third is NICE draft guidance on ID6608. The fourth is a price agreed for NHS use.
None of these has a published date. GSK says decisions in other regions are expected in the coming months. That statement does not name the UK.
Dr Norah Terrault, Chief of Gastroenterology and Hepatology at USC Keck Medical Center, is quoted in GSK’s release. She said: “This is the start of a new era in treating people living with CHB.” She is a US clinician. The quote comes from the sponsor.
Tony Wood, GSK’s Chief Scientific Officer, said US patients now have “the potential to achieve functional cure”. Whether UK patients gain the same chance is the open question for bepirovirsen NHS planners.
Readers tracking pending approvals can use the FDA drug approval decisions tracker. A comparable UK access question for another GSK medicine is covered in NHS access for dostarlimab in rectal cancer.
